We have observed
11 EP applications
Andrew John Sharples
has served for within the last five+ years.
(We consider all applications which have an EP A1 or A2 publication dated after June 15, 2013).
Please note, that we only count EP applications,
in which the name of the patent attorney is explicitly mentioned as representative.
These EP applications are:
RESTRICTED IMMUNOGLOBULIN HEAVY CHAIN MICE
CHLAMYDIA ANTIGENS AND USES THEREOF
VACCINES AND COMPOSITIONS AGAINST STREPTOCOCCUS PNEUMONIAE
PYRROLIDINE DERIVATIVES AS SELECTIVE GLYCOSIDASE INHIBITORS AND USES THEREOF
METHODS FOR PREPARATION OF MACROCYCLIC POLYESTER OLIGOMER VIA HETEROGENEOUS CATALYSIS
COLD BLOCK WITH EMBEDDED CHAMBERED BEVERAGE TAP
HUMANIZED IL-6 AND IL-6 RECEPTOR
MODIFIED NICOTINIC COMPOUNDS AND RELATED METHODS
Cell carrier and cell carrier containment devices containing regenerative cells
LATERAL FLOW IMMUNOASSAY FOR COMPLEMENT ACTIVATION AND METHODS OF USE FOR POINT-OF-CARE ASSESSMENT OF COMPLEMENT-ASSOCIATED DISORDERS
USE OF GALECTIN-3 FOR DETECTING AND PROGNOSING HEART FAILURE AFTER ACUTE CORONARY SYNDROME